ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 872

Spontaneous Remission In Patients Fulfilling The 2010 Classification Criteria For Rheumatoid Arthritis: The Impact Of Duration Of Joint Swelling

Ellen Sauar Norli1, Elisabeth Lie2, Gina Hetland Brinkmann3, Olav Bjørneboe4, Halvor Nygaard5, Anne Julsrud Haugen3, Patrik Stolt6, Cathrine Thunem7, Tore K. Kvien2 and Maria Mjaavatten2, 1Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway, 2Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Østfold Hospital Trust, Fredrikstad, Norway, 4Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway, 5Dept. of Rheumatology, Revmatismesykehuset Lillehammer, Lillehammer, Norway, 6Dept. of Rheumatology, Innlandet Hospital Trust, Brumunddal, Norway, 7Dept. of Rheumatology, Betanien Hospital, Skien, Norway

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Early Rheumatoid Arthritis and classification criteria

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Identifying Rheumatoid Arthritis in At-Risk Populations

Session Type: Abstract Submissions (ACR)

Background/Purpose:

In 2010 the new ACR/EULAR classification criteria for rheumatoid arthritis (RA criteria) were published. The prospects for early diagnosis and treatment have increased over the past decades, partly driven by the theory of a window of opportunity. The theory even implies the possibility of preventing development of RA if aggressive treatment is started early. We wanted to study the 2-year outcome of patients with arthritis of less than 16 weeks duration who fulfilled the RA criteria at baseline, according to the duration of joint swelling at first visit.

Methods:

1084 patients (age 18-75 years) were included in the NOR-VEAC (Norwegian Very Early Arthritis Clinic) study from 2004 to 2010, i.e. before the RA criteria were implemented.

Patients with crystal arthritis, septic arthritis, osteoarthritis and arthritis due to trauma were excluded. 234 patients (21.6%) fulfilled the RA criteria at baseline. 202 of these had information about DMARD use and were included in the current study, and168 (83.2%) had 2-year follow-up data.

The relationship between spontaneous resolution of arthritis (defined as no swollen joints at last visit and never used DMARDs) and duration of joint swelling, as well as other factors, was examined. Duration was treated as a non-linear continuous variable as well as divided into categories. Mann-Whitney U, Fisher’s exact and Chi-Square tests were used for the statistical analyses.

Results:

Duration of joint swelling [median (25-75 percentiles)] was 64 (38-83) days, mean (SD) age 52 (14) years, 62% were females, 60% anti-CCP positive, and 69% anti-CCP and/or RF positive. 23/202 (11.4%) had spontaneous resolution of arthritis.

There was a statistically significant relationship between duration of disease and tendency of spontaneous resolution of arthritis (Mann-Whitney U p=0.01). In cases with very short (0-2 weeks) duration, the arthritis resolved without DMARDs in 9/23 patients (39.1%). The corresponding proportion for 2-6 weeks duration was 5/36 (13.9%), and for >6 weeks duration 9/143 (6.3%). The patients with resolving arthritis less often had positive anti-CCP (p<0.001),were more seldom current daily smokers (p=0.01) and had less RA criteria points (p=0.02). There were no significant differences between the groups with regard to sex (p=0.50), age (p=0.28), 68-swollen (p=0.34) and 28-tender (p=0.97) joint counts, SR (p=0.42), CRP (p=0.50), BMI (p=0.51), fatigue (p=0.93), joint pain (p=0.13), patient global (p=0.28), assessor global (p=0.37), HAQ (p=0.27) or distribution of mono-, oligo- and polyarthritis (p=0.62).

Conclusion:

When the duration of joint swelling was very short, the arthritis resolved without initiation of DMARD treatment in a considerable proportion of patients who fulfilled the RA criteria at baseline. Patients with arthritis of more than 6 weeks duration experienced spontaneous resolution less frequently.


Disclosure:

E. S. Norli,
None;

E. Lie,

Pfizer Inc,

5,

Roche Pharmaceuticals,

5,

Abbott Immunology Pharmaceuticals,

5,

Bristol-Myers Squibb,

5;

G. H. Brinkmann,
None;

O. Bjørneboe,
None;

H. Nygaard,
None;

A. J. Haugen,
None;

P. Stolt,
None;

C. Thunem,
None;

T. K. Kvien,
None;

M. Mjaavatten,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/spontaneous-remission-in-patients-fulfilling-the-2010-classification-criteria-for-rheumatoid-arthritis-the-impact-of-duration-of-joint-swelling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology